ArticleHereditas2025
Shengjiang Powder alleviates oxidative stress damage and fibrosis in mice with atherosclerosis concurrent with non-alcoholic fatty liver disease.
Article in Hereditas, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the effects of "Shengjiang Powder", a representative formula for "simultaneous treatment of liver and heart," on liver tissue inflammation and fibrosis in mice with atherosclerosis(AS) concurrent with non-alcoholic fatty liver disease (NAFLD).
methodsTen wild-type male C57/B6J mice were assigned to the control group, and 40 ApoE -/- mouse were randomly divided into the model group, atorvastatin group, and traditional Chinese medicine (TCM) treatment groups. The model group, atorvastatin group, and TCM treatment groups were fed a high-fat Western diet for 12 weeks. Atorvastatin and TCM groups were administered via gavage, while the control group and model group received sterile purified water via gavage for 12 weeks. Serum levels of ALT, AST, TRIG, TC, LDL, as well as liver tissue levels of SOD, MDA, and GSH were measured. HE staining was used to evaluate liver tissue morphology and inflammatory infiltration. Western blot was used to detect the effect of Shengjiang Powder on the activation of AMPK/mTOR signaling pathway. Network pharmacology analysis was performed beforehand to identify potential targets of Shengjiang Powder in regulating fatty liver and atherosclerosis, with AMPK identified as a key target.
resultsCompared with the model group, the Shengjiang Powder treatment reduced serum levels of TRIG, TC, and LDL (P < 0.05), increased liver SOD and GSH activity (P < 0.01), decreased MDA (P < 0.01), alleviated liver steatosis, reduces the area of aortic sinus plaques, improved hepatic steatosis and inflammation, inhibited the expression of inflammatory factors and activated the AMPK/mTOR signaling pathway, consistent with the network pharmacology prediction that AMPK is a critical regulatory target.
conclusionTreatment with "Shengjiang Powder," a representative formula for "simultaneous treatment of liver and heart," can slow the progression of atherosclerosis and concurrent NAFLD. The dosage shows a positive correlation with efficacy, and this effect is related to the regulation of liver oxidative stress and inflammation-induced fibrosis pathways.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.